Stock A092040 AMICOGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Amicogen, Inc.

Equities

A092040

KR7092040005

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
7,600 KRW -1.81% Intraday chart for Amicogen, Inc. +2.29% +0.53%
Mar. 20 Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 654,430 483,674 730,075 620,699 379,320 412,059
Enterprise Value (EV) 1 674,500 497,167 729,365 662,875 491,053 523,099
P/E ratio 16.3 x 5,635 x 23.4 x 165 x -8.12 x -13 x
Yield - - - - - -
Capitalization / Revenue 6.92 x 4.2 x 6.3 x 4.97 x 2.63 x 2.58 x
EV / Revenue 7.14 x 4.32 x 6.3 x 5.31 x 3.4 x 3.27 x
EV / EBITDA 61.3 x 66.6 x 57.7 x 108 x 63.5 x 37.5 x
EV / FCF -57.4 x -42.6 x -197 x -41.8 x -10.5 x -6.75 x
FCF Yield -1.74% -2.35% -0.51% -2.39% -9.49% -14.8%
Price to Book 5.14 x 3.96 x 4.77 x 3.33 x 2.88 x 2.34 x
Nbr of stocks (in thousands) 38,383 38,010 38,025 39,099 39,105 54,505
Reference price 2 17,050 12,725 19,200 15,875 9,700 7,560
Announcement Date 3/22/19 3/16/20 3/17/21 3/22/22 3/21/23 3/20/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 94,522 115,181 115,856 124,881 144,296 159,904
EBITDA 1 11,006 7,463 12,644 6,143 7,739 13,953
EBIT 1 2,225 -2,591 2,645 -4,627 -4,926 689.4
Operating Margin 2.35% -2.25% 2.28% -3.71% -3.41% 0.43%
Earnings before Tax (EBT) 1 53,132 -880.3 40,814 9,663 -50,571 -23,230
Net income 1 40,168 86.72 31,604 3,733 -47,220 -23,289
Net margin 42.5% 0.08% 27.28% 2.99% -32.72% -14.56%
EPS 2 1,046 2.258 822.0 96.00 -1,195 -583.6
Free Cash Flow 1 -11,746 -11,678 -3,698 -15,862 -46,589 -77,536
FCF margin -12.43% -10.14% -3.19% -12.7% -32.29% -48.49%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/22/19 3/16/20 3/17/21 3/22/22 3/21/23 3/20/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 20,070 13,493 - 42,176 111,733 111,040
Net Cash position 1 - - 710 - - -
Leverage (Debt/EBITDA) 1.823 x 1.808 x - 6.865 x 14.44 x 7.958 x
Free Cash Flow 1 -11,746 -11,678 -3,698 -15,862 -46,589 -77,536
ROE (net income / shareholders' equity) 30% -0.15% 18.4% 2.23% -22.7% -10.6%
ROA (Net income/ Total Assets) 0.7% -0.69% 0.63% -0.83% -0.73% 0.1%
Assets 1 5,700,835 -12,658 5,017,363 -448,259 6,449,036 -24,234,043
Book Value Per Share 2 3,316 3,211 4,022 4,761 3,370 3,226
Cash Flow per Share 2 319.0 565.0 810.0 688.0 517.0 446.0
Capex 1 10,883 19,260 13,853 47,309 45,908 62,516
Capex / Sales 11.51% 16.72% 11.96% 37.88% 31.82% 39.1%
Announcement Date 3/22/19 3/16/20 3/17/21 3/22/22 3/21/23 3/20/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AMICOGEN, INC. Stock Amicogen, Inc.
+0.53% 308M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
ARGENX SE Stock argenx SE
+5.47% 22.94B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
GENMAB A/S Stock Genmab A/S
-5.85% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+313.59% 8.49B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A092040 Stock
  4. Financials Amicogen, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW